Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. reported a net loss of $149.3 million for fiscal year 2025, with no revenue generated during the period. The company's operating loss was $156.4 million, primarily driven by research and development expenses of $109.2 million and general and administrative expenses of $47.2 million. The company maintained a strong liquidity position with total current assets of $196.4 million, including $45.4 million in cash and cash equivalents and $145.5 million in short-term investments. Total assets stood at $225.2 million against total liabilities of $44.0 million, resulting in stockholders' equity of $181.2 million. The company used $128.3 million in operating cash flow but generated $134.3 million from investing activities, primarily from the maturity of short-term investments. Basic and diluted net loss per share was $2.00, with weighted average shares outstanding of 61.4 million.

Key Takeaways